Charles River Laboratories International Inc

CRL remains in a Stage 2 advancing regime within a sideways long-term trend. A Bullish Exhaustion pattern highlights waning upside momentum, yet price is now pulling back into rising 9 and 21 EMA support, presenting a tactical buy opportunity for continuation.

• ↑H2 operating margin expected >500bps above H1 on restructuring
• ↑PathoQuest buy enhances NGS capabilities for long-term growth
• ↓Organic revenue forecast to drop 0.5–1.5%, indicating growth headwinds